mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.
Shen C, Hu H, Cai Y, Ling J, Zhang J, Wu Z, Xie X, Huang M, Wang H, Kang L, Lan P, Wu X, Liu G, Wan Y, Zhou Z, Huang Y, Li F, Wang H, Ma T, Luo S, Cai Y, Shi L, Deng Y.
Shen C, et al. Among authors: zhou z.
Ann Transl Med. 2022 Feb;10(4):171. doi: 10.21037/atm-21-6731.
Ann Transl Med. 2022.
PMID: 35280386
Free PMC article.